Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A debate is raging between activists over whether treating HIV when CD4 cells are high is scientifically sound.
Among people engaged in HIV care in the United States, rates of ARV therapy usage and undetectable viral loads increased in seven years.
New results from the NA-ACCORD study, involving more than 45,000 North American people living with HIV enrolled in one of 20 cohorts, indicate...
Some states are lagging behind others in terms of getting people in need of HIV treatment started on medications in a timely fashion.
New report says starting antiretroviral (ARV) therapy with a CD4 count above 500 doesn’t decrease the risk of AIDS or death from any cause.
These data, from the largest study of its kind conducted so far, were published online September 8 in AIDS.
A new study shows that a disproportionate number of people living with HIV—notably women, African Americans and older adults—are p...
Starting antiretroviral (ARV) treatment early—perhaps before CD4 counts drop below 500—significantly reduces the risk of death, ac...
The biggest HIV science conference of the year proves that there’s a lot more to living long and well with HIV than antiretrovirals.
There are now multiple lines of evidence supporting the earlier initiation of antiretroviral (ARV) therapy than is currently recommended. But...
A new non-nuke, the apparent cure of an HIV-positive patient receiving a bone marrow transplant and the possibility of earlier...
Emerging data suggest that starting antiretroviral therapy earlier than is currently recommended provides even greater protection against illn...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.